Institutional Equities
|
|
- Earl Jennings
- 5 years ago
- Views:
Transcription
1 Event Update Institutional Equities Aurobindo Pharma 10 September 2018 Reuters: ARBP.NS; Bloomberg: ARBP IN Acquires Dermatology and Oral Solids Businesses Of Sandoz Aurobindo Pharma s (APL) acquisition of Sandoz s product portfolio (dermatology and oral solids) for US$900mn will fetch a similar amount in incremental sales (30% from dermatology products and the rest from oral solids) in the first full year post transaction closure (six to nine months from the announcement). The transaction values the portfolio at 1x sales and 4x-5x EBITDA. The valuation is apparently attractive, but the acquired product portfolio s sales are rapidly declining. The acquisition is in line with APL s history of acquiring commoditised assets and executing them profitably. The acquisition has both strategic benefits and will also be tactically accretive to earnings imminently. Key positives from the acquisition 1) Our estimates indicate that the acquisition price is significantly lower than the net replacement value for any new player who wishes to pursue the same for approval. 2) APL gets know-how of developing dermatology products including some complex ones without incrementally investing in the same. About one-third of the dermatology products inherited from the transaction have two or less competitors. 3) Gets ready access to an experienced sales force which allows it to reach out to dermatologists that contribute to a significant majority of prescriptions in the space. 4) Gets access to manufacturing capacities (dermatology and oral solids) which are currently under-utilised. 5) Expands manufacturing footprint in the US, which is important looking at rising impetus on local manufacturing in the US. 6) Access to low-cost funding allows APL to generate earnings accretion from the transaction. 7) Existing EBITDA margins are strong and at par with company margins. The margins will deteriorate with incremental competition, but APL has two years lead to establish supply chain efficiencies and restructure existing operations Key challenges 1) A large part of the oral solid portfolio is commoditised and has a median competitive intensity of seven players per molecule. Hence, it will be a challenge for APL to turn this around. 70% of US$900mn sales will be derived from the oral solids portfolio. 2) The dermatology portfolio is attractive now, but it is expected to decline every year as there is rising competitive intensity with every passing year. The pace of decline in the dermatology portfolio is the key uncertainty that APL has assumed through the transaction. 3) About one-fifth of the oral solids portfolio has two or less competitors and hence represents a potentially declining market. 4) APL s balance sheet will be significantly leveraged post acquisition (debt-to-equity ratio of ). Federal Trade Commission (FTC)-related divestments: Out of 300 products acquired, we see APL having a presence in 50 of those molecules and hence these can potentially become candidates for divestment. The overlap exists entirely in oral solids and not in topicals. Outlook and valuation: We have revised our earnings estimates for APL to include the recent acquisition (Sandoz portfolio and Apotex business in Europe). We assume transaction closure timeline as early FY20 for European operations of Apotex and Sandoz portfolio. Based on our revised EPS estimate for FY20 (Rs54), we have revised our target price for APL to Rs864 (from Rs764 earlier) which is based on 16x P/E multiple on FY20E earnings. We have also downgraded our rating on APL to Accumulate (from Buy earlier) as the stock price has run up sharply. ACCUMULATE Sector: Pharmaceuticals CMP: Rs801 Target Price: Rs864 Upside: 8% Vishal Manchanda Research Analyst vishal.manchanda@nirmalbang.com Madhurima Kane Research Associate madhurima.kane@nirmalbang.com Key Data Current Shares O/S (mn) Mkt Cap (Rsbn/US$bn) 469.2/ Wk H / L (Rs) 827/527 Daily Vol. (3M NSE Avg.) 3,548,208 Price Performance (%) 1 M 6 M 1 Yr Aurobindo Pharma Nifty Index Source: Bloomberg
2 Exhibit 1: Key financials Net sales 1,39,552 1,50,899 1,64,998 1,75,629 2,56,511 EBITDA 31,881 34,343 37,885 38,263 57,345 Net profit 20,221 22,962 24,198 23,485 31,580 EPS (Rs) EPS growth (%) (2.9) 34.4 EBITDA margin (%) P/E (x) P/BV (x) EV/EBITDA (x) RoCE (%) RoE (%) Transaction details APL has entered into a definitive agreement with the US-based Sandoz Inc. to acquire the latter s dermatology and oral solids businesses for an upfront purchase price of US$0.9bn in cash including potential upside in near-term earn-out and additional potential earn-out on the product pipeline in later years. The acquired businesses are expected to register sales amounting to US$900mn (12 months post deal closure) and margins in line with existing consolidated margins of APL. The acquisition gives APL access to 300 products (dermatology and oral solids). Around one-third of the acquired products are topical, while the rest are oral solids. In terms of value, 30% of the acquired product portfolio s sales come from dermatology products. FTC may require APL to divest certain products as a condition for deal closure. Our analysis suggests that APL and Sandoz have an overlap in around 50 products, which are all oral solids and largely commoditised. There is no overlap in topical portfolio. APL gains three manufacturing facilities at Hicksville - NY (Derma) Melville,- NY(Derma) Wilson and NC (OSD). All these facilities have significant under-utilised capacities. Is the valuation attractive? Apparently the deal appears to be a steal as it values the divested portfolio of products at 1x sales and 4-5x EBITDA, which is way below the acquisition multiples we have seen in the past. Lupin paid 9x sales for Gavis and Cipla paid 2.5x sales for Invagen. The deal was also well contested with several private equity players and a Chinese player also in the fray. While the valuation is attractive on the face of it, the acquired assets represent some challenges and the primary one being that the portfolio is expected to witness rising competitive intensity over time leading to deterioration of margins and rapidly declining sales. APL may look at managing the challenge through building supply chain efficiency and leveraging the assets it has secured for expanding the revenue stream. The potential reasons behind APL bidding more aggressively than the others could be its successful track record of turning around marginally profitable or lossmaking assets. APL has traditionally been a volume player and it has the knack of executing a commoditised portfolio. Will the margins sustain? The margins of the acquired businesses will be comparable to existing business margins of APL (approximately 20%) in the first full year of operations post deal closure. The deal is expected to close in the next six to nine months. The manufacturing assets currently operate at lower capacity utilisation which when leveraged fully will aid margins. In addition it also gains access to a sales force which gives it access to health care practitioners who are responsible for a significant majority of prescriptions in the dermatology space. The branded presence may be leveraged for in-licensing brands and support in-house 505 (b) (2) efforts in dermatology. Our net replacement value estimate suggests that valuation is fair APL has acquired a portfolio comprising 300 products which include authorised generics, in-licensed assets and filed/approved ANDAs. Looking at the transaction from a net replacement value perspective, we find the valuation reasonable and should give APL the strength to compete even in a commoditised environment. The acquisition gives APL immediate access to 300 products, which otherwise would have taken it around 8-10 years to file (based on the historical filing trend) and a cumulative R&D expenditure of close to Rs40bn (US$600mn). In addition, it would have invested a similar amount as capex for setting up the manufacturing facilities. Impact on APL s earnings performance The deal will be significantly accretive in the first full year of operation itself. The acquired business will have EBITDA margin in line with existing consolidated margin. Competitive pressure is likely to increase with time and exert pressure on margins. While new competition will lead to margin pressure, APL has two years from now to start making efforts and restructure the operations to ensure that the business margins remain on track. We believe APL can sustainably enjoy 18%-20% EBITDA margin from the acquired businesses through gradual restructuring and building supply chain efficiency. We expect the cost of funding the acquisitions to be around 3% - 4%. We have factored in 24% EBITDA margin from the acquired businesses in FY20E, which should erode to 18% in FY21E. 2 Aurobindo Pharma
3 Exhibit 2: Overlap of Sandoz and APL s product portfolios Form Route Overlap with APL Tablets Oral 38 Tablets Delayed release 1 Tablets Extended release - Suspension Oral 4 Suspension Inhalation - Capsules Oral 5 Capsules Delayed release 1 Capsules Extended release - Lotion, cream, ointment, gel - - Injectable - 4 Solution - 1 Others - - Total - 54 Source: Medicaid, Nirmal Bang Institutional Equities Research Exhibit 3: Change in estimates (Rsmn) New estimates Old estimates Change (%) FY19E FY20E FY19E FY20E FY19E FY20E Net sales 1,75,629 2,56,511 1,76,780 1,85,054 (0.7) 38.6 EBITDA 38,263 57,345 40,105 40,315 (4.6) 42.2 Margin (%) bps 266 bps PAT 23,485 31,580 25,646 27,938 (8.4) 13.0 Margin (%) (123) bps (149) bps EPS (Rs) (8.4) Aurobindo Pharma
4 Financial statement Exhibit 4: Income statement Net sales 1,39,552 1,50,899 1,64,998 1,75,629 2,56,511 % growth Raw material costs 61,621 64,343 67,527 72,654 1,07,510 Staff costs 15,426 17,678 21,308 23,652 35,520 R&D expenses 4,699 5,430 6,665 6,918 10,154 Other expenditure 25,925 29,106 31,612 34,141 45,981 Total expenditure 1,07,671 1,16,556 1,27,113 1,37,366 1,99,166 EBITDA 31,881 34,343 37,885 38,263 57,345 % growth EBITDA margin (%) Other income 2,038 1,159 1,020 1,540 2,003 Interest costs 2, ,182 4,421 Gross profit 77,931 86,556 97,471 1,02,975 1,49,000 % growth Depreciation 3,924 4,276 5,580 6,473 11,911 PBT & exceptional items 27,429 30,558 32,381 32,148 43,015 Exceptional Items ,000 Profit before tax 27,429 30,558 32,381 31,248 42,015 % growth (0.7) 33.8 Tax 7,207 7,596 8,183 7,763 10,435 Effective tax rate (%) Share of MI and associates PAT after share of MI & associates 20,251 22,967 24,232 23,488 31,582 % growth (2.9) 34.5 EPS (Rs) % growth (2.9) 34.4 Exhibit 6: Balance sheet Equity Reserves 72,288 93,133 1,16,218 1,37,978 1,67,833 Net worth 72,873 93,719 1,16,804 1,38,564 1,68,419 Minority interest Net deferred tax liabilities ,353 2,353 2,353 Short-term loans 36,727 29,027 40,313 43,229 63,789 Long-term loans 7,428 1,814 4,512 4,061 72,255 Other non-current Liabilities Liabilities 1,17,527 1,25,465 1,64,559 1,88,784 3,07,392 Net block 33,804 40,831 47,366 54,893 1,01,831 CWIP 8,359 12,374 13,995 14,995 15,995 Intangible assets & goodwill 8,115 9,715 19,676 19,676 19,676 Other non-current assets 5,980 7,514 8,136 8,136 8,136 Inventories 40,561 43,305 58,584 63,032 93,272 Debtors 46,067 27,653 30,844 32,864 48,232 Cash 8,003 5,135 12,616 25,033 72,730 Other current assets 8,313 15,968 19,835 19,835 19,835 Total current assets 1,02,944 92,062 1,21,879 1,40,763 2,34,068 Creditors 24,570 21,547 26,274 28,269 41,831 Other current liabilities 17,105 15,482 20,218 21,411 30,483 Total current liabilities 41,675 37,029 46,492 49,680 72,315 Net current assets 61,268 55,033 75,386 91,083 1,61,753 Total assets 1,17,527 1,25,466 1,64,560 1,88,784 3,07,392 Exhibit 4: Exhibit 5: Cash flow EBIT 29,996 31,276 33,189 32,462 46,467 (Inc.)/dec. in working capital (9,804) 3,367 (12,872) (3,280) (22,973) Cash flow from operations 20,191 34,643 20,318 29,181 23,495 Other income (2,038) (1,159) (1,020) (1,540) (2,003) Other expenses , ,000 Depreciation 3,924 4,276 5,580 6,473 11,911 Tax paid (-) (7,207) (7,596) (8,183) (7,763) (10,435) Net cash from operations 15,108 30,417 18,554 27,251 23,968 Capital expenditure (-) (14,984) (16,917) (23,698) (15,000) (59,850) Net cash after capex ,501 (5,144) 12,251 (35,882) Other investment activities 1,170 (375) 398 1,540 2,003 Cash from financial activities 2,218 (15,994) 12,228 (1,374) 81,576 Opening cash balance 4,491 8,003 5,135 12,616 25,033 Closing cash balance 8,003 5,134 12,616 25,033 72,730 Change in cash balance 3,512 (2,868) 7,482 12,417 47,697 Exhibit 5: Exhibit 7: Key ratios Y/E March FY16 FY17 FY18 FY19E FY20E Profitability & return ratios EBITDA margin (%) EBIT margin (%) Net profit margin (%) RoE (%) RoCE (%) Working capital & liquidity ratios Receivables (days) Inventory (days) Payables (days) Current ratio (x) Quick ratio (x) Valuation ratios EV/sales (x) EV/EBITDA (x) P/E (x) P/BV (x) Aurobindo Pharma
5 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Sep-18 Institutional Equities Rating track Date Rating Market price (Rs) Target price (Rs) 7 April 2016 Buy May 2016 Buy August 2016 Buy November 2016 Buy February 2017 Buy May 2017 Buy June 2017 Accumulate July 2017 Accumulate August 2017 Buy November 2017 Accumulate February 2017 Buy May 2018 Buy August 2018 Buy September 2018 Accumulate Rating track graph Not Covered Covered 5 Aurobindo Pharma
6 DISCLOSURES This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: I/We, Vishal Manchanda, the research analysts and Madhurima Kane, the research associate are the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 6 Aurobindo Pharma
7 Disclaimer Stock Ratings Absolute Returns BUY > 15% ACCUMULATE -5% to15% SELL < -5% This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. Copyright of this document vests exclusively with NBEPL. Our reports are also available on our website Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com , Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com /8101, Michael Pillai Dealing Desk michael.pillai@nirmalbang.com /8103, Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 301/302, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai Board No. : /1; Fax. : Aurobindo Pharma
Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY
3QCY18 Result Update Institutional Equities Sanofi India Reuters: SANO.BO; Bloomberg: SANL IN Robust Performance Sanofi India s revenues in 3QCY18 stood at Rs7,438mn which were above our/consensus estimate
More informationInstitutional Equities
1QFY19 Result Update Institutional Equities Aurobindo Pharma 13 August 2018 Reuters: ARBP.NS; Bloomberg: ARBP IN One-offs Impact Margin Aurobindo Pharma (APL) reported 1QFY19 revenues of Rs42,503mn which
More informationGillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance
2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings
More informationGillette India. Institutional Equities. 1QFY18 Result Update
1QFY18 Result Update Institutional Equities Gillette India 14 November 2017 Reuters: GILE.NS; Bloomberg: GILL IN Robust Growth In Operating Margin Gillette India s or GIL s overall top-line performance
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationJamna Auto Industries
2QFY19 Result Update Institutional Equities Jamna Auto Industries Reuters: JMNA.NS; Bloomberg: JMNA IN Performance Below Expectations; Retain Buy Due To Strong Outlook Jamna Auto s 2QFY19 earnings were
More informationInstitutional Equities
4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account
More informationIndian Oil Corporation
3QFY18 Result Update Institutional Equities Indian Oil Corporation 1 February 2018 Reuters: IOC.BO; Bloomberg: IOCL IN Earnings Outperformance On Account Of Inventory Gains Indian Oil Corporation (IOCL)
More informationPower Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution
2QFY19 Result Update Power Mech Projects 21 November 218 Reuters: POMP.BO; Bloomberg: POWM IN Strong Order Book Drives Robust Execution Power Mech Projects (PMPL) posted 2QFY19 consolidated revenues of
More informationITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%
4QFY18 Result Update Institutional Equities ITC 17 May 2018 Reuters: ITC.NS; Bloomberg: ITC IN Tracking Expectations ITC s growth in 4QFY18 was modest and in line with expectations. On the revenue side,
More informationDalmia Bharat Enterprises
Result Update Dalmia Bharat Enterprises 1 November 218 Reuters: DALA.BO; Bloomberg: DBEL IN Performance In Line; Stock Under Review Post Odisha Cement Amalgamation Dalmia Bharat Enterprises (DBEL) reported
More informationNESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY
Event Update Institutional Equities NESCO 27 August 2018 Reuters: NSEN.NS; Bloomberg: NSE IN Revenues From Bombay Exhibition Centre May Take A Hit This event update relates to an application made on 14
More informationEBITDA 5,076 3, , EBITDA
Result Update Ambuja Cements 21 February 218 Reuters: ABUJ.BO; Bloomberg: ACEM IN Healthy Volume Growth, Operating Costs Under Control Ambuja Cements (ACEM) reported a good set of numbers for owing to
More informationPunjab National Bank
4QFY18 Result Update Institutional Equities Punjab National Bank 16 May 2018 Reuters: PNB.BO; Bloomberg: PNB IN Prompt Corrective Action Looms Punjab National Bank (PNB) reported its 4QFY18 results with
More informationNestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%
1QCY18 Result Update Institutional Equities Nestle India 11 May 218 Reuters: NEST.BO; Bloomberg: NEST IN Resurgence Continues Nestle India (NEST) reported strong overall performance during 1QCY18 driven
More informationMold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY
Conference Update Institutional Equities Mold-Tek Packaging 20 August 2018 Reuters: MOLT.BO; Bloomberg: MTEP IN Promising Growth Outlook We recently interacted with the management of Mold-Tek Packaging
More informationThermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL
3QFY18 Result Update Institutional Equities Thermax 8 February 2018 Reuters: THMX.BO; Bloomberg: TMX IN Healthy Execution, But Margins Disappoint Thermax posted healthy execution in 3QFY18 with standalone
More informationIndian Oil Corporation
4QFY18 Result Update Institutional Equities Indian Oil Corporation 24 May 2018 Reuters: IOC.BO; Bloomberg: IOCL IN Subdued Earnings Because Of Lower GRM and Higher Expenses Indian Oil Corporation (IOCL)
More informationInstitutional Equities
1QFY19 Result Update Institutional Equities Dr. Reddy s Laboratories 27 July 2018 Reuters: REDY.BO; Bloomberg: DRRD IN Drug Pipeline In Place, But Regulatory Hurdles Testing Patience Dr. Reddy s Laboratories
More informationInstitutional Equities
Company Update Institutional Equities Dr. Reddy s Laboratories 5 September 2017 Reuters: REDY.BO; Bloomberg: DRRD IN Suboxone Generic Opportunity To Be Lucrative, Can Sustain For Longer Time The district
More informationBata India. Institutional Equities. 1QFY19 Result Update BUY
1QFY19 Result Update Institutional Equities Bata India 23 July 2018 Reuters: BATA.BO; Bloomberg: BATA IN Strong Margin Improvement To Drive Consensus EPS Upgrade Bata India s (BIL) YoY net sales growth
More informationSouth Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018
4QFY18 Result Update Institutional Equities South Indian Bank 15 May 2018 Reuters: SIBK.BO; Bloomberg: SIB IN Asset Quality Pain To Ease Hereafter South Indian Bank (SBL) reported 4QFY18 results with the
More informationPunjab National Bank
Company Update Punjab National Bank 19 September 2018 Reuters: PNB.BO; Bloomberg: PNB IN Concerns Remain; Assign Accumulate We take Punjab National Bank (PNB) out from Under Review and assign an Accumulate
More informationEicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN
Management Meet Update Institutional Equities Eicher Motors 17 July 2018 Reuters: EICH.NS; Bloomberg: EIM IN We had a meeting with the management of Eicher Motors (EML) recently. Following are the key
More informationSequent Scientific. Institutional Equities. 1QFY19 Result Update BUY
1QFY19 Result Update Sequent Scientific 13 August 2018 Reuters: SEQU.BO; Bloomberg: SEQ IN Regulatory Changes And Adverse Forex Movement Dampens Momentum Sequent Scientific or SSL s revenues at Rs2,369mn
More informationMangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY
Result Update Mangalam Cement 16 February 2018 Reuters: MGLC.BO; Bloomberg: MGC IN Higher Operating costs Hurt Performance Mangalam Cement (MGC) reported a weak performance for on account of higher operating
More informationInstitutional Equities
3QFY18 Result Update Institutional Equities Atul Auto 15 February 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Drag Profitability Atul Auto s (AAL) 3QFY18 earnings missed our expectations
More informationVoltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE
1QFY19 Result Update Voltas 13 August 218 Reuters: VOLT.BO; Bloomberg: VOLT IN EMPS Shines, UCP Proves Its Mettle Again Voltas reported consolidated revenues of Rs21.5bn for 1QFY19, up 11% YoY and 5%/6%
More information26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN
2QFY19 Result Update Maruti Suzuki India 26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN Better-than-expected Margins; Retain Buy Maruti Suzuki India (MSIL) s 2QFY19 earnings were 18% above our estimate
More informationPower Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy
2QFY18 Result Update Power Mech Projects 23 November 217 Reuters: POMP.BO; Bloomberg: POWM IN Strong Business Scalability Likely; Retain Buy Power Mech Projects (PMPL) posted 2QFY18 consolidated revenues
More informationEBITDA 6,223 6,511 (4.4) 5, EBITDA
Result Update Institutional Equities Ambuja Cements 26 July 218 Reuters: ABUJ.BO; Bloomberg: ACEM IN Performance Beats Expectations, Sustainability Is Key Challenge Ambuja Cements (ACEM) reported steady
More informationACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE
Event Update Institutional Equities ACC 19 December 218 Reuters: ACC.BO; Bloomberg: ACC IN Capacity Expansion To Consolidate Presence In Central India ACC has announced 5.9mt capacity expansion by adding
More informationDabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE
4QFY18 Result Update Institutional Equities Dabur India 3 May 2018 Reuters: DABU.NS; Bloomberg: DABUR IN Growth Volatility Is Still Fairly High Dabur India s (DABUR) consolidated top-line performance in
More informationSwaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE
2QFY18 Result Update Institutional Equities Swaraj Engines 13 November 2017 Reuters: SWAR.BO; Bloomberg: SWE IN Strong Realisation Drives Earnings Growth Swaraj Engines (SEL) 2QFY18 earnings were 5% above
More informationTVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL
3QFY19 Result Update TVS Motor Company 23 January 2019 Reuters: TVSM.BO; Bloomberg: TVSL IN Better-Than-Expected Margins TVS Motor Company s 3QFY19 performance was above our expectations as it reported
More informationHindustan Unilever. Institutional Equities. 4QFY18 Result Update
4QFY18 Result Update Institutional Equities Hindustan Unilever 15 May 2018 Reuters: HLL.BO; Bloomberg: HUVR IN Reaping Rewards Of Consistency 4QFY18 was the third consecutive quarter wherein Hindustan
More informationDabur India. Institutional Equities. 1QFY19 Result Update
1QFY19 Result Update Institutional Equities Dabur India 2 August 2018 Reuters: DABU.NS; Bloomberg: DABUR IN Consistency Is Key To The Game Dabur India s (DABUR) operating performance in 1QFY19 was better
More informationEBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA
1QFY19 Result Update The Ramco Cements 3 August 218 Reuters: TRCE.BO; Bloomberg: TRCL IN Challenging Business Environment Aptly Handled The Ramco Cements (TRCL) reported a stable operating performance
More informationPNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018
4QFY18 Result Update Institutional Equities PNB Housing Finance 4 May 2018 Reuters: PNBH.NS; Bloomberg: PNBHOUSI IN Continued Display of Embedded Scalability PNB Housing Finance (PNBHF) reported 4QFY18
More informationInstitutional Equities
Economy Update March CPI Inflation/February IIP 15 April 2019 CPI Inflation Inches Up To 2.86%; IIP Growth Plunges To 0.1% Consumer Price Index or CPI inflation in March 2019 stood at 2.86%, slightly above
More informationKarnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN
4QFY18 Result Update Institutional Equities Karnataka Bank 17 May 2018 Reuters: KBNK.NS; Bloomberg: KBL IN Plucky Bank And Low Hanging Fruit Karnataka Bank (KBL) reported 4QFY18 results with the key strategic
More informationInstitutional Equities
December 2017 Quarter Result Preview Institutional Equities Oil & Gas Sector 8 January 2018 Higher Crude Oil Prices To Result In Inventory Gains We expect 60%/4.4%/3.7%/6.5% QoQ growth in the December
More informationHindustan Unilever. Institutional Equities. 1QFY19 Result Update
1QFY19 Result Update Institutional Equities Hindustan Unilever 17 July 218 Reuters: HLL.BO; Bloomberg: HUVR IN Breakout Growth Hindustan Unilever (HUVR) has delivered strong volume led top-line growth
More informationThe Ramco Cements. Institutional Equities. Event Update BUY
Event Update The Ramco Cements 21 December 2018 Reuters: TRCE.BO; Bloomberg: TRCL IN Capacity Expansion To Boost Its Presence In Andhra & Telangana The Ramco Cements (TRCL) has announced 3.15mt cement
More informationInstitutional Equities
2QFY18 Result Update Institutional Equities KCP 5 December 2017 Reuters: KCP.BO; Bloomberg: KCPL IN Other Income Drives PAT; High International Coal Price Is Cause For Concern KCP reported a weak set of
More informationInstitutional Equities
Economy Update August CPI Inflation/ July IIP 14 September 2018 CPI Inflation Moderates To 3.69% YoY; IIP Growth Slows To 6.6% YoY Consumer Price Index or CPI inflation stood at 3.69% in August 2018, below
More informationEBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA
Result Update The India Cements 12 November 218 Reuters: ICMN.BO; Bloomberg: ICEM IN Lackluster Performance The India Cements (ICEM) reported a listless operating performance in because of the sustained
More informationManappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018
3QFY18 Result Update Institutional Equities Manappuram Finance 9 February 2018 Reuters: MNFL.BO; Bloomberg: MGFL IN The Glitter Is Back In Gold Loans Manappuram Finance (MFL) reported its 3QFY18 results
More informationCrompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely
4QFY15 Result Update Crompton Greaves 29 May 2015 Reuters: CROM.BO; Bloomberg: CRG IN Overseas Losses Continue; More Business Exits Likely The 4QFY15 performance of Crompton Greaves (CGL) was below expectation
More informationCrisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport
3QCY17 Result Update Institutional Equities Crisil 18 October 2017 Reuters: CRSL.BO; Bloomberg: CRISIL IN Weak SME Rating Revenues & Currency Movement Play Spoilsport Crisil s 3QCY17 performance was below
More informationIFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.
3QFY18 Result Update Institutional Equities IFB Industries Reuters: IFBI.BO; Bloomberg: IFBI IN Healthy Revenues, Strong Gross Margin; Retain Buy IFB Industries (IFB) posted a healthy 17% YoY rise in net
More informationInstitutional Equities
Management Meet Update Institutional Equities Kaya Reuters: KAYA.NS; Bloomberg: KAYA IN We interacted with the management of Kaya at an investor conference held by us recently. Following are the key takeaways:
More information2,09,057 1,85,859 2,17, (4.1) NIM
2QFY19 Result Update Institutional Equities State Bank of India 6 November 2018 Reuters: SBI.BO; Bloomberg: SBIN IN Domestic Credit Growth Improves Materially State Bank of India (SBI) reported its 2QFY19
More informationConsolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE
Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 2904 Recommendation CMP Target Price BUY Rs. 312 Rs. 443 Better times ahead! reported a good set of numbers in
More information18,948 15,784 18, NIM
3QFY18 Result Update IndusInd Bank 12 January 2018 Reuters: INBK.BO; Bloomberg: IIB IN Alive to all Opportunities IndusInd Bank (IBL) reported its 3QFY18 results with the key strategic takeaways being
More informationBharat Financial Inclusion
3QFY18 Result Update Bharat Financial Inclusion Reuters: BHAF.NS; Bloomberg: BHAFIN IN 31 January 2018 Customer Acquisition Accelerates Meaningfully Bharat Financial Inclusion (BFIL) reported its 3QFY18
More informationTimken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy
4QFY16 Result Update Institutional Equities Timken India 23 May 2016 Reuters: TMKN.BO; Bloomberg: TIMK IN Margin Expansion Leads To Huge Growth In Profit; Retain Buy Timken India (TIL), the leading manufacturer
More informationMuthoot Finance. Institutional Equities. 3QFY18 Result Update. Funding Cost Decline Combines With Operating Leverage BUY.
3QFY18 Result Update Institutional Equities Muthoot Finance 12 February 2018 Reuters: MUTT.BO; Bloomberg: MUTH IN Funding Cost Decline Combines With Operating Leverage Muthoot Finance (MFL) reported its
More informationSwiss Glascoat Equipments
Management Meet Update Institutional Equities Swiss Glascoat Equipments 28 December 17 Reuters: SWGE.BO; Bloomberg: SWGE IN We had a meeting with the management of Swiss Glascoat Equipments (SGEL) recently
More informationInstitutional Equities
3QFY15 Result Update Institutional Equities GlaxoSmithKline Consumer Healthcare Reuters: GLSM.BO; Bloomberg: SKB IN 4 February 2015 Price Hike Leads To Sales Growth Glaxo SmithKline Consumer Healthcare
More informationInitiating Coverage. Uflex Ltd.
2904 Recommendation CMP Target Price BUY Rs. 283 Rs. 444 Better times ahead! reported a good set of numbers for the year FY18 and for Q4. Sales for the quarter increase by 11.8% YoY to Rs 1809.8 Cr and
More information3,746 2,551 3, NIM
4QFY17 Result Update Institutional Equities Capital First 11 May 2017 Reuters: CAPF.BO; Bloomberg: CAFL IN Net Interest Income Up, But Offset By Elevated Credit Costs Although the net interest income or
More informationDalmia Bharat Enterprises
Result Update Institutional Equities Dalmia Bharat Enterprises Reuters: DALA.BO; Bloomberg: DBEL IN 14 August 218 Listless Performance, But Valuation Premium Continues Dalmia Bharat Enterprises (DBEL)
More informationBajaj Electricals. Institutional Equities. 3QFY15 Result Update
3QFY15 Result Update Institutional Equities Bajaj Electricals 13 February 2015 Reuters: BJEL.BO; Bloomberg: BJE IN Final Phase Of Transition Pain; Retain Buy Bajaj Electricals (BJE) posted 3QFY15 revenue
More informationCARE Ratings. Institutional Equities. 2QFY18 Result Update BUY
2QFY18 Result Update Institutional Equities CARE Ratings 17 November 217 Reuters: CREI.BO; Bloomberg: CARE IN Mixed Performance CARE Ratings (CARE) reported an increase of 12.3% in revenues for 2QFY18
More informationMuthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017
1QFY18 Result Update Institutional Equities Muthoot Finance 10 August 2017 Reuters: MUTT.BO; Bloomberg: MUTH IN Gold Loan Business Continues To Glitter Strong profitability numbers of Muthoot Finance (MFL)
More information9,500 7,914 8, NIM
3QFY18 Result Update Institutional Equities Federal Bank 16 January 2018 Reuters: FED.BO; Bloomberg: FB IN Quarter Typifies Balanced Growth Engine Federal Bank (FBL) reported 3QFY18 results with the key
More informationDalmia Bharat Enterprises
Result Update Dalmia Bharat Enterprises Reuters: DALA.BO; Bloomberg: DBEL IN 22 May 218 Healthy Performance Led By Good Volume Growth Dalmia Bharat Enterprises (DBEL) reported a healthy performance for
More informationPNB Housing Finance. Institutional Equities. 2QFY19 Result Update BUY. Relatively Soft Quarter Not Structural In Nature.
2QFY19 Result Update Institutional Equities PNB Housing Finance 6 November 2018 Reuters: PNBH.NS; Bloomberg: PNBHOUSI IN Relatively Soft Quarter Not Structural In Nature PNB Housing Finance (PNBHF) reported
More informationE&P To Stay Strong; Consumer Segment To Revive
Management Meet Update Institutional Equities Bajaj Electricals 30 August 2017 Reuters: BJEL.BO; Bloomberg: BJE IN E&P To Stay Strong; Consumer Segment To Revive We had a meeting with the management of
More informationMuthoot Finance. Institutional Equities. 2QFY18 Result Update BUY
2QFY18 Result Update Institutional Equities Muthoot Finance 10 November 2017 Reuters: MUTT.BO; Bloomberg: MUTH IN Gold Loan Business Really Glitters Strong profitability numbers of Muthoot Finance (MFL)
More informationInstitutional Equities
1QFY18 Result Update Institutional Equities Cipla 14 August 2017 Reuters: CIPL.NS; Bloomberg: CIPLA IN Gross Margin Improvement Is A Positive Surprise Cipla s revenues in 1QFY18 stood at Rs35,251mn, showing
More informationBata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%
Management Meet Update Bata India Reuters: BATA.BO; Bloomberg: BATA IN On Right Track We had a meeting recently with Mr. R. K. Gupta, Chief Financial Officer (CFO) of Bata India (BIL) to understand recent
More informationCadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514
3QFY15 Result Update Institutional Equities Cadila Healthcare 11 February 2015 Reuters: CADI.BO; Bloomberg: CDH IN Stable Performance Cadila Healthcare s (CHL) 3QFY15 earnings were in line with our expectations
More informationEBITDA 5,019 4,211 5, EBITDA
Result Update Institutional Equities Dalmia Bharat Reuters: DALA.BO; Bloomberg: DBEL IN Outperformance Likely To Continue Dalmia Bharat (DBL) reported a good set of numbers for, given the challenging environment
More informationInstitutional Equities
Economy Update Institutional Equities May Inflation/April Index of Industrial Production 13 June 2018 CPI Inflation At 4.9%; IIP Growth Also At 4.9% Consumer Price Index or CPI inflation in India stood
More informationEBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA
Result Update Institutional Equities The India Cements 28 May 218 Reuters: ICMN.BO; Bloomberg: ICEM IN Fall In Realisation, Higher Operating Costs Hurt Performance The India Cements (ICEM) reported a weak
More informationAtul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017
Management Meet Update Atul Auto 23 August 2017 Reuters: ATUL.BO; Bloomberg: ATUL IN We had a meeting with the management of Atul Auto (AAL) recently to gauge its performance in the aftermath of a relatively
More informationSun Pharmaceutical Industries
Event Update Institutional Equities Sun Pharmaceutical Industries Reuters: SUN.BO; Bloomberg: SUNP IN Surprise Audit Of Halol Unit By USFDA - Outcome Is Key As per a report in the Business Standard newspaper
More information93,707 77,814 90, NIM
1QFY18 Result Update Institutional Equities HDFC Bank Reuters: HDBK.BO; Bloomberg: HDFCB IN Higher Fee Income Offsets Higher Provisioning HDFC Bank s net interest income or NII grew 20% in 1QFY18 driven
More information9,251 7,812 8, NIM
4QFY15 Result Update Institutional Equities IndusInd Bank 17 April 2015 Reuters: INBK.BO; Bloomberg: IIB IN Yet Another Robust Performance IndusInd Bank s 4QFY15 profit beat our estimate by 12%. Its bottom-line
More informationLa Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536
4QFY17 Result Update La Opala RG 11 May 217 Reuters: LAOP.BO; Bloomberg: LOG IN Revenues Soar, But Margins Take A Hit La Opala RG (LORL) reported revenues of Rs761mn for 4QFY17, up 41% YoY. The stellar
More information9,807 8,007 9, NIM
1QFY16 Result Update Institutional Equities IndusInd Bank Reuters: INBK.BO; Bloomberg: IIB IN Yet Another Stellar Performance IndusInd Bank s 1QFY16 profit beat our estimate by 4%. Its bottom-line grew
More informationMuthoot Finance. Institutional Equities. 2QFY19 Result Update. Weak quarter not structural in any way BUY. 10 December 2018
2QFY19 Result Update Institutional Equities Muthoot Finance 10 December 2018 Reuters: MUTT.BO; Bloomberg: MUTH IN Weak quarter not structural in any way Muthoot Finance (MFL) reported its 2QFY19 results
More informationInstitutional Equities
March 2018 Quarter Result Preview Institutional Equities FMCG Sector 6 April 2018 Strong Fundamentals To Support High-teen Growth We expect the companies in our FMCG coverage universe to maintain their
More informationInstitutional Equities
10 April 2019 4QFY19 Result Preview Gains Versus El Nino Headwind Holds The Key; Retain Buy We remain positive on and retain our Buy call on it based on 24% upside to our blended target price of Rs1,134
More informationPunjab National Bank
4QFY15 Result Update Institutional Equities Punjab National Bank 11 May 2015 Reuters: PNB.BO; Bloomberg: PNB IN Asset Quality Disappointment Continues Punjab National Bank (PNB) posted dismal 4QFY15 performance,
More informationPunjab National Bank
1QFY16 Result Update Institutional Equities Punjab National Bank 29 July 2015 Reuters: PNB.BO; Bloomberg: PNB IN Some Respite On Asset Quality Front Punjab National Bank (PNB) reported moderate 1QFY16
More informationHindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY
3QFY18 Result Update Institutional Equities Hindustan Unilever 18 January 2018 Reuters: HLL.BO; Bloomberg: HUVR IN Robust Performance Maintained Hindustan Unilever or HUL reported a robust set of numbers
More informationManappuram Finance. Institutional Equities. 3QFY17 Result Update BUY
3QFY17 Result Update Institutional Equities Manappuram Finance 9 February 2017 Reuters: MNFL.BO; Bloomberg: MGFL IN Profitability Beats Expectations Amid Some Spike In Loan Delinquency Strong Profit &
More informationHindustan Unilever. Institutional Equities. 2QFY19 Result Update
2QFY19 Result Update Institutional Equities Hindustan Unilever 15 October 2018 Reuters: HLL.BO; Bloomberg: HUVR IN Best Proxy In A VUCA World Hindustan Unilever s (HUVR) overall performance in 2QFY19 was
More informationPunjab National Bank
1QFY18 Result Update Institutional Equities Punjab National Bank 3 August 2017 Reuters: PNB.BO; Bloomberg: PNB IN Asset Quality Continues To Disappoint Punjab National Bank s (PNB) annualised loan slippage
More informationMuthoot Finance. Institutional Equities. 1QFY19 Result Update
1QFY19 Result Update Institutional Equities Muthoot Finance 6 September 2018 Reuters: MUTT.BO; Bloomberg: MUTH IN Sequential Gold Loan AUM Growth Accelerates Further Muthoot Finance (MFL) reported its
More informationState Bank of India. Institutional Equities. 1QFY18 Result Update
1QFY18 Result Update Institutional Equities State Bank of India 14 August 2017 Reuters: SBI.BO; Bloomberg: SBIN IN Merger With Associate Banks Accentuates The Pain State Bank of India s (SBI) annualised
More informationVoltas. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Capital Goods CMP: Rs309 Target Price: Rs325 Upside: 5% 23 December 2016
Management Meet Update Institutional Equities Voltas Reuters: VOLT.BO; Bloomberg: VOLT IN We had a meeting with the management of Voltas recently to get the latest business update. While the management
More informationHindustan Unilever. Institutional Equities. Company Update. Faster And Stronger BUY. Sector: FMCG CMP: Rs1,350 Target Price: Rs1,570 Upside: 16%
Company Update Institutional Equities Hindustan Unilever Reuters: HLL.BO; Bloomberg: HUVR IN Faster And Stronger We reiterate our positive view on the Home and Personal Care (HPC) space and continue to
More informationLa Opala RG. Institutional Equities. 1QFY18 Result Update
1QFY18 Result Update La Opala RG 31 August 2017 Reuters: LAOP.BO; Bloomberg: LOG IN Flattish YoY Performance La Opala RG (LORL) reported revenues of Rs475mn for 1QFY18, up 0.6% YoY, but significantly below
More informationFederal Bank. Institutional Equities. Management Meet Update
Management Meet Update Institutional Equities Federal Bank 11 June 2018 Reuters: FED.BO; Bloomberg: FB IN Several Good Things in Store We recently met the CEO of Federal Bank (FBL), Mr Shyam Srinivasan
More informationInstitutional Equities
2QFY13 Result Update Institutional Equities Reliance Infrastructure 7 November 2012 Reuters: RELIN.BO; Bloomberg: RELI IN Project Execution On Track Reliance Infrastructure reported revenue decline of
More informationState Bank of India. Institutional Equities. 3QFY19 Result Update BUY
3QFY19 Result Update State Bank of India 4 February 2019 Reuters: SBI.BO; Bloomberg: SBIN IN Domestic Growth Continues To Accelerate State Bank of India (SBI) reported its 3QFY19 results with the key pointers
More information